Parameter | 200CONT (n = 64) | 200CROSS (n = 33) | 400CONT (n = 65) | 400CROSS (n = 34) |
---|---|---|---|---|
Age, years, mean (SD) | 53.2 (10.4) | 52.4 (10.1) | 52.1 (11.5) | 52.1 (10.6) |
Male sex, n (%) | 63 (98.4) | 33 (100) | 60 (92.3) | 32 (94.1) |
Race, n (%) | ||||
Asian | 5 (7.8) | 3 (9.1) | 5 (7.7) | 1 (2.9) |
Black or African American | 9 (14.1) | 4 (12.1) | 8 (12.3) | 1 (2.9) |
Māori | 0 | 0 | 2 (3.1) | 0 |
White | 48 (75.0) | 26 (78.8) | 49 (75.4) | 31 (91.2) |
Body mass index, kg/m2, mean (SD) | 31.9 (5.9) | 33.9 (6.1) | 31.8 (5.8) | 33.4 (5.9) |
Duration since gout diagnosis, years, mean (SD) | 15.8 (9.5) | 13.8 (9.0) | 12.9 (10.0) | 12.0 (9.3) |
Number of gout flares in past 12 months, mean (SD) | 7.7 (13.6) | 7.1 (5.8) | 8.1 (8.2) | 7.1 (5.9) |
Type of gout flare prophylaxis, n (%) | ||||
Colchicine | 55 (85.9) | 24 (72.7) | 53 (81.5) | 30 (88.2) |
NSAID | 6 (9.4) | 3 (9.1) | 12 (18.5) | 4 (11.8) |
Both | 1 (1.6) | 0 | 2 (3.1) | 0 |
Other/missing | 4 (6.3) | 6 (18.2) | 2 (3.1) | 0 |
sUA, mg/dl, mean (SD) | ||||
At core study baselinea | 5.4 (1.6) | 4.9 (1.3) | 5.0 (1.5) | 5.3 (1.4) |
At extension study start | 4.0 (2.2) | 5.2 (1.7) | 2.9 (1.7) | 5.5 (2.4) |